Page 1

Report: Treating Refractory Hematological Malignancies Category: Healthcare

Insert Image Height - 3.60 Width – 4.98

www.researchonglobalmarkets.com


Report: Treating Refractory Hematological Malignancies Report Details

• Publish date: 29th Aug, 2013

• • • • • • • •

Number of slides: 37 Geographic coverage: Global Available format: PDF, CD, Hardcopy Price for Single User License: USD 2,500 Price for Site License: USD 5,000 Price for Global User License: USD 7,500 Delivery Time: Within 1 business day Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google Wallet, PayPal www.researchonglobalmarkets.com


Report: Treating Refractory Hematological Malignancies Report Insights

• Treating Refractory Hematological Malignancies unfold a host of competition and commercial opportunities, thereby attracting swarming competition • There is severe competition amongst the companies to launch new therapies for this indication

www.researchonglobalmarkets.com


Report: Treating Refractory Hematological Malignancies Report Coverage

• Overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts • Competition and commercial opportunity in pursuing this therapy area has been highlighted • Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them • Detailed financial and competitive analysis of the companies leading in the race to launch new therapies for this indication • Key M&A activities in the last 5 years and a list of products in early or late stages of development available for in-licensing are highlighted

www.researchonglobalmarkets.com


Report: Treating Refractory Hematological Malignancies Table of Contents

• • • • • • • • • •

Executive Summary Investment Drivers of The Select Companies Covered Myelodysplastic syndrome (MDS) Acute Myelogenous Leukemia (AML) Competitive Landscape: RR/ High-Risk MDS and RR AML Competitive Landscape: Untreated/ Newly Diagnosed MDS and AML Key Milestones Launch Timeline and Commercial Opportunity of Late-stage Pipeline (RR MDS and RR AML) Drivers of M&A / Licensing Deals in MDS/ AML www.researchonglobalmarkets.com


Report: Treating Refractory Hematological Malignancies List of Figures and Tables

Figures: • • • • • • • • • • • •

Monotherapy response rates (crc) in aml QUIZARITINIB - phiib comparable efficacy with lower doses Qtc prolongation at various doses of quizartinib Long term survivors in phase 2 - treated with quizartinib Quizartinib market opportunity in us in aml Overall survival for aml pts less than 60 year old with flt3 itd mutation Proposed phiii trial of quizartinib Phiii trial design – ontime Itt analysis: survival data for refractory mds pts Best bone marrow (bm) responses after rig. Iv Phii trial design – ontarget Phiii trial design - ontrac

www.researchonglobalmarkets.com


Report: Treating Refractory Hematological Malignancies List of Figures and Tables (Continued)

Tables: • • • • • • • • • • • •

Revised international prognosis scoring system (ipss-r) Competitive landscape: rr/ high-risk mds and rr aml Competitive landscape: untreated/ newly diagnosed mds and aml Launch timeline and market potential Select m&a and licensing deals in last 5 years - 2007 to 2012 Select m&a and licensing deals opportunities NPV VALUATION- base case Npv valuation - early approval Competitive landscape - select late and mid stage drug targeting aml Select jak 2/1 inhibitors: mid- to late-stage pipeline Npv valuation table 12 Competition in rr mds/ aml - select late- to mid- stage compounds

www.researchonglobalmarkets.com


Interested in this report? To view more details regarding this premium market research report, Please click here

For further information, get in touch with us: E-mail: support@researchonglobalmarkets.com Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600 About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports Industry Segments Automotive & Transport

Consumer goods

Agriculture

Food and Beverage

Energy and Utilities

Public Sector

Manufacturing & Construction

Healthcare

Media & Entertainment

IT, Telecom & Electronics

Services

Others

www.researchonglobalmarkets.com

Treating refractory hematological malignancies unfold a host of opportunities  

For the complete report ,visit us at: http://bit.ly/hematological-malignancies Or, get in touch with us at : support@researchonglobalmarket...

Advertisement